A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520

Leukemia and Lymphoma

Volumn 57, Issue 10, 2016, Pages 2359-2369

  Puvvada, Soham D ^a   Li, Hongli ^b   Rimsza, Lisa M ^c   Bernstein, Steven H ^d   Fisher, Richard I ^e   LeBlanc, Michael ^b   Schmelz, Monika ^c   Glinsmann Gibson, Betty ^c   Miller, Thomas P ^a   Maddox, Anne Marie ^f   Friedberg, Jonathan W ^d   Smith, Sonali M ^g   Persky, Daniel O ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

Author keywords

CIITA; DLBCL; HDAC inhibition; MHC Class II expression; non Hodgkin lymphoma; SWOG

Indexed keywords

BELINOSTAT; HISTONE H3; HISTONE H4; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SULFONAMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; FEVER; FOLLOW UP; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; QT PROLONGATION; QTC INTERVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPREGULATION; URINARY TRACT INFECTION; VOMITING; CANCER STAGING; CLINICAL TRIAL; DIFFUSE LARGE B CELL LYMPHOMA; DRUG RESISTANCE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; RETREATMENT; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HLA-DR ANTIGENS; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; RETREATMENT; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 84954287601     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1135431     Document Type: Article

References (57)

1. J.O.Armitage, D.D.Weisenburger New approach to classifying non-Hodgkin’s lymphomas:clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–2795.
2. C.Gisselbrecht, B.Glass, N.Mounier,. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190.
3. D.J.Andorsky, R.E.Yamada, J.Said,. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232–4244.
4. L.M.Rimsza, R.A.Roberts, T.P.Miller,. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors:a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004;103:4251–4258.
5. L.M.Rimsza, R.Roberts, A.E.Campo,. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood. 2006;107:1101–1107.
6. G.W.Beresford, J.M.Boss CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat Immunol. 2001;2:652–657.
7. S.C.Lee, A.Bottaro, R.A.Insel Activation of terminal B cell differentiation by inhibition of histone deacetylation. Mol Immunol. 2003;39:923–932.
8. A.Muhlethaler-Mottet, L.A.Otten, V.Steimle,. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 1997;16:2851–2860.
9. J.M.Boss, P.E.Jensen Transcriptional regulation of the MHC class II antigen presentation pathway. Curr Opin Immunol. 2003;15:105–111.
10. K.Masternak, A.Muhlethaler-Mottet, J.Villard,. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 2000;14:1156–1166.
11. V.Steimle, C.A.Siegrist, A.Mottet,. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science. 1994;265:106–109.
12. S.LeibundGut-Landmann, J.M.Waldburger, M.Krawczyk,. Mini-review:specificity and expression of CIITA, the master regulator of MHC class II genes. Eur J Immunol. 2004;34:1513–1525.
13. K.L.Wright, J.P.Ting Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol. 2006;27:405–412.
14. S.LeibundGut-Landmann, J.M.Waldburger, C.Reis e Sousa,. MHC class II expression is differentially regulated in plasmacytoid and conventional dendritic cells. Nat Immunol. 2004;5:899–908.
15. J.M.Waldburger, T.Suter, A.Fontana,. Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J Exp Med. 2001;194:393–406.
16. J.A.Plumb, P.W.Finn, R.J.Williams,. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther. 2003;2:721–728.
17. I.Velichutina, R.Shaknovich, H.Geng,. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 2010;116:5247–5255.
18. F.J.van Kemenade, F.M.Raaphorst, T.Blokzijl,. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001;97:3896–3901.
19. N.Li, D.Zhao, M.Kirschbaum,. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci U S A. 2008;105:4796–4801.
20. D.Z.Qian, Y.Kato, S.Shabbeer,. Targeting tumor angiogenesis with histone deacetylase inhibitors:the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12:634–642.
21. V.M.Richon, T.W.Sandhoff, R.A.Rifkind,. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014–10019.
22. R.Tao, E.F.de Zoeten, E.Ozkaynak,. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med. 2007;13:1299–1307. Nov.
23. W.S.Xu, R.B.Parmigiani, P.A.Marks Histone deacetylase inhibitors:molecular mechanisms of action. Oncogene. 2007;26:5541–5552.
24. R.D.Morin, M.Mendez-Lago, A.J.Mungall,. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
25. L.Pasqualucci, D.Dominguez-Sola, A.Chiarenza,. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature. 2011;471:189–195.
26. N.L.Steele, J.A.Plumb, L.Vidal,. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008;14:804–810.
27. P.Gimsing, M.Hansen, L.M.Knudsen,. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur J Haematol. 2008;81:170–176.
28. H.Z.Lee, V.E.Kwitkowski, P.L.Del Valle,. FDA Approval:Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma. Clin Cancer Res. 2015;21:2666–2670.
29. B.D.Cheson, S.Horning, J.B.Coiffier,. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
30. S.T.Wilkinson, K.A.Vanpatten, D.R.Fernandez,. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood. 2012;119:1459–1467.
31. M.Schmelz, S.Montes-Moreno, M.Piris,. Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphoma. Haematologica. 2012;97:1614–1616.
32. R.A.Roberts, C.M.Sabalos, M.L.LeBlanc,. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Invest. 2007;87:979–997.
33. I.S.Lossos, D.K.Czerwinski, M.A.Wechser,. Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies. Leukemia. 2003;17:789–795.
34. H.Chang, J.A.Blondal, S.Benchimol,. p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin’s lymphoma cell lines. Leuk Lymphoma. 1995;19:165–171.
35. E.KaplanEaM. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481.
36. D.R.Cox Regression models and life tables (with discussion). J Roy Statist Soc Serv. 1972;34:187–220.
37. M.Ahmadzadeh, L.A.Johnson, B.Heemskerk,. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537–1544.
38. J.Fourcade, P.Kudela, Z.Sun,. PD-1 is a regulator of NY-ESO-1-specific CD8 + T cell expansion in melanoma patients. J Immunol. 2009;182:5240–5249.
39. A.J.Gehring, Z.Z.Ho, A.T.Tan,. Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2009;137:682–690.
40. R.Yamamoto, M.Nishikori, T.Kitawaki,. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood. 2008;111:3220–3224.
41. S.P.Patel, R.Kurzrock PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847–856.
42. C.Vogel, S.Abreu Rde, D.Ko,. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol Syst Biol.2010;6:400.
43. E.Vire, C.Brenner, R.Deplus,. The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 2006;439:871–874.
44. F.Tie, T.Furuyama, J.Prasad-Sinha,. The Drosophila Polycomb Group proteins ESC and E(Z) are present in a complex containing the histone-binding protein p55 and the histone deacetylase RPD3. Development. 2001;128:275–286.
45. J.van der Vlag, A.P.Otte Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet. 1999;23:474–478.
46. O.A.O’Connor, M.L.Heaney, L.Schwartz,. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol. 2006;24:166–173.
47. M.Crump, B.Coiffier, E.D.Jacobsen,. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol. 2008;19:964–969.
48. Y.Boumber, A.Younes, G.Garcia-Manero Mocetinostat (MGCD0103):a review of an isotype-specific histone deacetylase inhibitor. Expert Opin Investig Drugs. 2011;20:823–829.
49. G.Dasmahapatra, D.Lembersky, L.Kramer,. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 2010;115:4478–4487.
50. B.Holkova, M.Kmieciak, P.Bose,. Phase I trial of carfilzomib in combination with vorinostat (SAHA) in patients with relapsed/refractory B cell lymphomas. Blood. 2013;122:4375.
51. J.A.Barnes, R.Redd, E.Jacobsen,. Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma:results of a Phase II study. Blood. 2014;124:3055.
52. http://ClinicalTrials.gov., A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin’s Lymphoma. Available from:https://clinicaltrials.gov/ct2/show/NCT01460940?term=NCT01460940&rank=1 (Last accessed 05-25-15), ed, NCT01460940.
53. J.Kikuchi, T.Wada, R.Shimizu,. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood. 2010;116:406–417.
54. G.Lenz, G.Wright, S.S.Dave,. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–2323.
55. S.Monti, K.J.Savage, J.L.Kutok,. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851–1861.
56. P.Armand, A.Nagler, E.A.Weller,. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma:results of an international phase II trial. J Clin Oncol. 2013;31:4199–4206.
57. A.Diepstra, G.W.van Imhoff, H.E.Karim-Kos,. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin’s lymphoma. J Clin Oncol. 2007;25:3101–3108.